Trial reportNature medicine2026
Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trial.
Trial report in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04539964 (Vagus Nerve Stimulation Using the SetPoint System for Moderate to Severe Rheumatoid Arthritis), which is not on this map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Vagus Nerve Stimulation Using the SetPoint System for Moderate to Severe Rheumatoid Arthritis: The RESET-RA Study
Who cites it
23 citing papers in PubMed.
- Sacral nerve stimulation modulates disease activity and autonomic function in active rheumatoid arthritis: a randomized pilot study.Clinical rheumatology · 2026Trial
- An intelligent tribological hydrogel delivering 9,10-DiOH activates cuproptosis for comprehensive rheumatoid arthritis intervention.Materials today. Bio · 2026Article
- Vagus nerve stimulation in rheumatic diseases: linking autonomic nervous system regulation, inflammation, and clinical outcomes.Rheumatology international · 2026Review
- Prospects for Physical Therapy in Rheumatoid Arthritis: Literature Review.Healthcare (Basel, Switzerland) · 2026Review
- tVNS and obesity-related inflammation: a prospective sham-controlled randomized crossover study protocol.BMC psychology · 2026Article
- The new PORT needs the same old evidence-based standards.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2026Article
- Splenic neuromodulation as monotherapy and in combination with biologic or targeted synthetic DMARDs for difficult-to-treat rheumatoid arthritis (ConsiderRAte): a randomised, sham-controlled, early feasibility trial.EClinicalMedicine · 2026Article
- Review
- Bioelectronic Medicine: A New Horizon for Difficult-To-Treat Rheumatoid Arthritis.International journal of rheumatic diseases · 2026Article
- Transcutaneous Auricular Vagus Nerve Stimulation for Post-COVID-19 Condition: A Systematic Review and Critical Appraisal of Clinical Evidence.Journal of clinical medicine · 2026Review
- Vagus nerve stimulation limits colonic inflammation through distinct neuroimmune circuitry shaped by inflammatory history.bioRxiv : the preprint server for biology · 2026Article
- Neuroimmune Dynamics in Diseases of the Arterial Wall: Mechanistic Foundations and Translational Prospects.Current atherosclerosis reports · 2026Review
- Emerging trends in the management of difficult-to-treat rheumatoid arthritis: targeted treatments and non-pharmacological interventions.Rheumatology (Oxford, England) · 2026Review
- Open-Source Large Language Models Distilled DeepSeek-R1 Pose Challenges for On-Premises Clinical Deployment in Medical Diagnosis: A Comparative Study of Performance.Journal of medical systems · 2026Article
- Vagus nerve stimulation in Crohn's disease: long-term outcomes, mechanistic insights, and the promise of non-invasive approaches.Bioelectronic medicine · 2026Article
- Vagus nerve stimulation shows clinical benefits for RA in pivotal trial.Nature reviews. Rheumatology · 2026Article
- Pathogenic Drivers of Difficult-to-Treat Rheumatoid Arthritis: Synovium and Beyond.International journal of molecular sciences · 2026Review
- Electromagnetic neuromodulation for chronic pain: historical context, contemporary modalities, and evidence gaps.Frontiers in pain research (Lausanne, Switzerland) · 2026Review
- Interorgan Communications in Skeletal Pathophysiology: From Molecular Pathways to Multidisciplinary Therapies.Research (Washington, D.C.) · 2026Review
- Neurotransmitters as regulators of autoimmunity: mechanisms and translational targeting.NPJ autoimmunity · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The inflammatory reflex, in which vagus nerve signaling modulates cytokine production, is dysregulated in rheumatoid arthritis (RA). RESET-RA, a pivotal, double-blind, randomized, sham-controlled trial, evaluated a vagus nerve-targeted neuromodulation system for RA in 242 patients with inadequate response/intolerance to biological/targeted synthetic disease-modifying antirheumatic drugs. Patients were randomized to active or sham stimulation for 3 months, and then all received open-label stimulation with results reported to 12 months. The primary end point was 3-month American College of Rheumatology 20% (ACR20) response. ACR20 rates were higher with active simulation than with sham at 3 months (35.2% versus 24.2%, P = 0.0209), which further improved in open-label to 50.0% at 6 months and 52.8% at 12 months (all-completers). Adverse events occurred in a similar proportion of patients in both arms. Related serious adverse events (rate = 1.6%) were all perioperative, and resolved. Vagus nerve-mediated neuroimmune modulation for RA achieved its primary efficacy end point and produced durable clinical benefits with a favorable safety profile. ClinicalTrials.gov registration: NCT04539964 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.